HLB Life Science Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 122.15 million compared to KRW 854.14 million a year ago. Net loss was KRW 10,367.5 million compared to KRW 15,473.94 million a year ago.

Basic loss per share from continuing operations was KRW 103.6404 compared to KRW 155.936 a year ago. Diluted loss per share from continuing operations was KRW 103.6404 compared to KRW 155.936 a year ago. Basic loss per share was KRW 103.6404 compared to KRW 155.936 a year ago.